Plain-English translation of NCT06649851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called G-CSF (also known as Filgrastim) can protect your brain from damage caused by radiation and chemotherapy used to treat glioblastoma, an aggressive type of brain cancer. G-CSF is a protein that helps your bone marrow produce immune cells and has been shown to reduce inflammation and protect nerve cells in the brain. The study will compare people who receive standard cancer treatment plus G-CSF against those who receive standard cancer treatment alone, measuring effects on brain structure, memory, and thinking.
Radiation and chemotherapy save lives, but they can damage healthy brain tissue and cause problems with memory and thinking over time. Researchers want to know if this medication can reduce those side effects and help preserve brain health during and after cancer treatment.
You likely qualify if…
You likely don't qualify if…
You will first receive standard radiation therapy with chemotherapy over 6 weeks. If assigned to the G-CSF group, you will then receive injections of the medication — either at the hospital or self-administered at home — during breaks in your chemotherapy and for several months afterward. You will have multiple brain MRI scans and visits to assess how your brain is doing over the course of about 2 years total (6 weeks of radiation/chemo, up to 7 months of medication, and follow-up visits to monitor your progress).
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States